REDEFINE 3: A Research Study to See the Effects of CagriSema on Heart Disease in People Living With Obesity and Diseases in the Heart and Blood Vessels
Sponsor
Novo Nordisk A/S (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05669755
Collaborator
(none)
4,000
254
2
50.1
15.7
0.3
Study Details
Study Description
Brief Summary
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with obesity and cardiovascular disease. Participants will either get CagriSema or a dummy medicine which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will take one injection once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 3 years. Participants will have 22 clinic visits with the study doctor or study staff. Women cannot take part if pregnant, breastfeeding or plan to get pregnant during the study period. Women who are able to become pregnant must use highly effective birth control and will be counselled on the use of birth control.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
4000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Cardiovascular Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Obesity and Established Cardiovascular Disease
Anticipated Study Start Date
:
Mar 1, 2023
Anticipated Primary Completion Date
:
May 5, 2027
Anticipated Study Completion Date
:
May 5, 2027
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: CagriSema 2.4 mg/2.4 mg Participants will receive 2.4 milligrams (mg) cagrilintide and 2.4 mg semaglutide subcutaneously (s.c.) once-weekly after a dose escalation period of 16 weeks (0.25 mg of cagrilintide and 0.25 mg of semaglutide from weeks 0-4, 0.50 mg of cagrilintide and 0.50 mg of semaglutide from weeks 5-8, 1 mg of cagrilintide and 1 mg of semaglutide from weeks 9-12 and 1.7 mg of cagrilintide and 1.7 mg of semaglutide from weeks 13-16) during the maintenance period for 140 weeks . |
Drug: Cagrilintide
Participants will receive 2.4 mg cagrilintide s.c. once-weekly after a dose escalation period of 16 weeks for 140 weeks.
Drug: Semaglutide
Participants will receive 2.4 mg semaglutide s.c. once-weekly after a dose escalation period of 16 weeks for 140 weeks.
|
| Placebo Comparator: Placebo Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide s.c. once weekly for 156 weeks. |
Drug: Placebo
Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide subcutaneously.
|
Outcome Measures
Primary Outcome Measures
- To confirm non-inferiority of CagriSema 2.4 mg/2.4 mg versus placebo: Time to first occurrence of major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke [From baseline (week 0) to end of study (up to 163 weeks or more)]
Measured in months.
Secondary Outcome Measures
- To confirm superiority of CagriSema 2.4 mg/2.4 mg versus placebo: Time to first occurrence of MACE, a composite endpoint consisting of: CV death, non-fatal myocardial infarction and non-fatal stroke [From baseline (week 0) to end of study (up to 163 weeks or more)]
Measured in months.
- Time to first occurrence of an expanded MACE composite endpoint consisting of: CV death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation and unstable angina requiring hospitalisation [From baseline (week 0) to end of study (up to 163 weeks or more)]
Measured in months.
- Time to first occurrence of a composite heart failure endpoint consisting of: CV death, heart failure hospitalisation, and urgent heart failure visit [From baseline (week 0) to end of study (up to 163 weeks or more)]
Measured in months.
- Time to first occurrence of composite endpoint consisting of: all-cause death, non-fatal myocardial infarction and non-fatal stroke [From baseline (week 0) to end of study (up to 163 weeks or more)]
Measured in months.
- Time to occurrence of CV death [From baseline (week 0) to end of study (up to 163 weeks or more)]
Measured in months.
- Time to first occurrence of non-fatal myocardial infarction [From baseline (week 0) to end of study (up to 163 weeks or more)]
Measured in months.
- Time to first occurrence of non-fatal stroke [From baseline (week 0) to end of study (up to 163 weeks or more)]
Measured in months.
- Relative change in body weight [From baseline (week 0) to end of treatment (week 156)]
Measured in percentage (%).
- Change in waist circumference [From baseline (week 0) to end of treatment (week 156)]
Measured in centimeters (cm).
- Change in systolic blood pressure (SBP) [From baseline (week 0) to end of treatment (week 156)]
Measured in millimeters of mercury (mmHg).
- Change in diastolic blood pressure (DBP) [From baseline (week 0) to end of treatment (week 156)]
Measured in mmHg.
- Relative change in lipids: Total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol, triglycerides and free fatty acids [From baseline (week 0) to end of treatment (week 156)]
Measured in percentage.
- Change in glycated haemoglobin (HbA1c) [From baseline (week 0) to end of treatment (week 156)]
Measured in percentage.
- Change in Short Form 36 v2.0 acute (SF-36v2) [From baseline (week 0) to end of treatment (week 156)]
SF-36v2.0 is a 36-item commonly used generic clinical outcome assessment (COA) instrument measuring health-related quality of life and general health status across disease areas. The SF-36v2.0 for adults with a 1 week recall period (i.e. acute version) measures the individual overall health-related quality of life in 8 health domains (physical functioning, role-physical, bodily pain, general health, social functioning, role emotional, vitality and mental health). Furthermore, it includes two aggregated scores: a physical component summary score and a mental component summary score. The scores ranges from 0-100, higher scores indicates better health-related quality of life.
- Number of treatment emergent serious adverse events (TESAEs) [From baseline (week 0) to end of study (up to 163 weeks or more)]
Measured in count of events.
- Number of event adjudication committee (EAC)-confirmed malignant neoplasms [From baseline (week 0) to end of study (up to 163 weeks or more)]
Measured as count of events.
- Number of severe hypoglycaemic episodes (level 3) (only for participants with type 2 diabetes mellitus [T2D] at screening) [From baseline (week 0) to end of study (up to 163 weeks or more)]
Measured as count of events.
Eligibility Criteria
Criteria
Ages Eligible for Study:
55 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Male or female
-
Age above or equal to 55 years at the time of signing informed consent
-
Body mass index (BMI) greater than or equal to (>=) 30.0 kilograms per meter square (kg/m^2)
-
Established CVD as evidenced by at least one of the following:
-
Prior myocardial infarction
-
Prior stroke (ischemic or haemorrhagic stroke)
-
Symptomatic peripheral arterial disease (PAD) defined as at least one of the following:
-
Intermittent claudication with an Ankle-brachial index (ABI) less than (<) 0.85 at rest
-
Intermittent claudication with a >= 50% stenosis in a lower extremity peripheral artery documented by X-ray angiography, magnetic resonance (MR) angiography, computed tomography (CT) angiography or Doppler ultrasound
-
Prior revascularization procedure of a lower extremity peripheral artery
-
Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g., trauma or osteomyelitis)
For participants with T2D at screening the following inclusion criteria also apply:
-
Diagnosed with type 2 diabetes mellitus (T2D) >= 180 days before screening
-
HbA1c 7%-10% (53-86 millimoles per mole [mmol/mol]) (both inclusive), as measured by central laboratory at screening
-
Treatment with either:
-
Lifestyle intervention alone
-
1-3 marketed oral antidiabetic drugs (OAD)s (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose co-transporter 2 inhibitor (SGLT2i), dipeptidyl peptidase 4 (DPP4)-inhibitors, thiazolidinediones, or sulphonylureas (SU) as a single agent or in combination) according to local label
-
Basal insulin alone or in combination with up to two marketed OADs, all according to local label
Exclusion Criteria:
-
Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 60 days before screening
-
Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
-
Heart failure classified as being in New York Heart Association (NYHA) Class IV at screening
-
Treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist (RA) or a medication with GLP-1 activity within 90 days before screening
-
End stage renal disease defined as estimated glomerular filtration rate (eGFR) < 15 millileters per minutes per 1.732 (mL/min/1.73 m2), as measured by the central laboratory at screening
-
Chronic or intermittent haemodialysis or peritoneal dialysis
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Novo Nordisk Investigational Site | Birmingham | Alabama | United States | 32533 |
| 2 | Novo Nordisk Investigational Site | Beverly Hills | California | United States | 90211 |
| 3 | Novo Nordisk Investigational Site | Covina | California | United States | 91723 |
| 4 | Novo Nordisk Investigational Site | La Jolla | California | United States | 92037 |
| 5 | Novo Nordisk Investigational Site | Lomita | California | United States | 90717 |
| 6 | Novo Nordisk Investigational Site | Northridge | California | United States | 91325 |
| 7 | Novo Nordisk Investigational Site | Palm Springs | California | United States | 92262 |
| 8 | Novo Nordisk Investigational Site | Torrance | California | United States | 90502 |
| 9 | Novo Nordisk Investigational Site | Bridgeport | Connecticut | United States | 06610 |
| 10 | Novo Nordisk Investigational Site | Delray Beach | Florida | United States | 33445 |
| 11 | Novo Nordisk Investigational Site | Miami | Florida | United States | 33174 |
| 12 | Novo Nordisk Investigational Site | Wellington | Florida | United States | 33449 |
| 13 | Novo Nordisk Investigational Site | Roswell | Georgia | United States | 30076 |
| 14 | Novo Nordisk Investigational Site | Idaho Falls | Idaho | United States | 83404-7596 |
| 15 | Novo Nordisk Investigational Site | Gillespie | Illinois | United States | 62033 |
| 16 | Novo Nordisk Investigational Site | Skokie | Illinois | United States | 60077 |
| 17 | Novo Nordisk Investigational Site | Franklin | Indiana | United States | 46131 |
| 18 | Novo Nordisk Investigational Site | West Des Moines | Iowa | United States | 50265 |
| 19 | Novo Nordisk Investigational Site | Overland Park | Kansas | United States | 66211 |
| 20 | Novo Nordisk Investigational Site | Lexington | Kentucky | United States | 40503 |
| 21 | Novo Nordisk Investigational Site | Hammond | Louisiana | United States | 70403 |
| 22 | Novo Nordisk Investigational Site | West Monroe | Louisiana | United States | 71291 |
| 23 | Novo Nordisk Investigational Site | Flint | Michigan | United States | 48532 |
| 24 | Novo Nordisk Investigational Site | Festus | Missouri | United States | 63028 |
| 25 | Novo Nordisk Investigational Site | Saint Louis | Missouri | United States | 63136 |
| 26 | Novo Nordisk Investigational Site | Omaha | Nebraska | United States | 68198-6828 |
| 27 | Novo Nordisk Investigational Site | West Seneca | New York | United States | 14224 |
| 28 | Novo Nordisk Investigational Site | Westfield | New York | United States | 14787 |
| 29 | Novo Nordisk Investigational Site | Chapel Hill | North Carolina | United States | 27514 |
| 30 | Novo Nordisk Investigational Site | Durham | North Carolina | United States | 27710 |
| 31 | Novo Nordisk Investigational Site | Morehead City | North Carolina | United States | 28557 |
| 32 | Novo Nordisk Investigational Site | New Bern | North Carolina | United States | 28562 |
| 33 | Novo Nordisk Investigational Site | Fargo | North Dakota | United States | 58104 |
| 34 | Novo Nordisk Investigational Site | Cleveland | Ohio | United States | 44195 |
| 35 | Novo Nordisk Investigational Site | Maumee | Ohio | United States | 43537 |
| 36 | Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | United States | 19114 |
| 37 | Novo Nordisk Investigational Site | Chattanooga | Tennessee | United States | 37411 |
| 38 | Novo Nordisk Investigational Site | Dallas | Texas | United States | 75230 |
| 39 | Novo Nordisk Investigational Site | Fort Worth | Texas | United States | 76132 |
| 40 | Novo Nordisk Investigational Site | Houston | Texas | United States | 77061 |
| 41 | Novo Nordisk Investigational Site | Longview | Texas | United States | 75605 |
| 42 | Novo Nordisk Investigational Site | Lufkin | Texas | United States | 75904 |
| 43 | Novo Nordisk Investigational Site | Round Rock | Texas | United States | 78681 |
| 44 | Novo Nordisk Investigational Site | San Antonio | Texas | United States | 78212 |
| 45 | Novo Nordisk Investigational Site | San Antonio | Texas | United States | 78229 |
| 46 | Novo Nordisk Investigational Site | Schertz | Texas | United States | 78154 |
| 47 | Novo Nordisk Investigational Site | Sugar Land | Texas | United States | 77478 |
| 48 | Novo Nordisk Investigational Site | Waco | Texas | United States | 76708 |
| 49 | Novo Nordisk Investigational Site | Norfolk | Virginia | United States | 23510 |
| 50 | Novo Nordisk Investigational Site | Salem | Virginia | United States | 24153-6404 |
| 51 | Novo Nordisk Investigational Site | Winchester | Virginia | United States | 22601-3834 |
| 52 | Novo Nordisk Investigational Site | Wausau | Wisconsin | United States | 54401 |
| 53 | Novo Nordisk Investigational Site | Caba | Buenos Aires | Argentina | C1128 AAF |
| 54 | Novo Nordisk Investigational Site | Caba | Argentina | C1440AAD | |
| 55 | Novo Nordisk Investigational Site | Capital Federal | Argentina | C1056ABJ | |
| 56 | Novo Nordisk Investigational Site | Córdoba | Argentina | X5006IKK | |
| 57 | Novo Nordisk Investigational Site | Morón | Argentina | B1708IFF | |
| 58 | Novo Nordisk Investigational Site | Auchenflower | Queensland | Australia | 4066 |
| 59 | Novo Nordisk Investigational Site | Adelaide | South Australia | Australia | 5000 |
| 60 | Novo Nordisk Investigational Site | Leabrook | South Australia | Australia | 5068 |
| 61 | Novo Nordisk Investigational Site | Hobart | Tasmania | Australia | 7000 |
| 62 | Novo Nordisk Investigational Site | Joondalup | Western Australia | Australia | 6027 |
| 63 | Novo Nordisk Investigational Site | Porto Alegre | Rio Grande Do Sul | Brazil | 90430-001 |
| 64 | Novo Nordisk Investigational Site | Rio de Janeiro | RJ | Brazil | 22061-080 |
| 65 | Novo Nordisk Investigational Site | Campinas | Sao Paulo | Brazil | 13010-001 |
| 66 | Novo Nordisk Investigational Site | Campinas | Sao Paulo | Brazil | 13060-080 |
| 67 | Novo Nordisk Investigational Site | São José do Rio Preto | Sao Paulo | Brazil | 15090-000 |
| 68 | Novo Nordisk Investigational Site | São Paulo | Sao Paulo | Brazil | 01223-001 |
| 69 | Novo Nordisk Investigational Site | São Paulo | Sao Paulo | Brazil | 01228-000 |
| 70 | Novo Nordisk Investigational Site | São Paulo | Sao Paulo | Brazil | 01228-200 |
| 71 | Novo Nordisk Investigational Site | Bankya | Bulgaria | 1320 | |
| 72 | Novo Nordisk Investigational Site | Dimitrovgrad | Bulgaria | 6400 | |
| 73 | Novo Nordisk Investigational Site | Panagyurishte | Bulgaria | 4500 | |
| 74 | Novo Nordisk Investigational Site | Pazardzhik | Bulgaria | 4401 | |
| 75 | Novo Nordisk Investigational Site | Plovdiv | Bulgaria | 4002 | |
| 76 | Novo Nordisk Investigational Site | Ruse | Bulgaria | 7013 | |
| 77 | Novo Nordisk Investigational Site | Sliven | Bulgaria | 8800 | |
| 78 | Novo Nordisk Investigational Site | Sofia | Bulgaria | 1233 | |
| 79 | Novo Nordisk Investigational Site | Sofia | Bulgaria | 1431 | |
| 80 | Novo Nordisk Investigational Site | Sofia | Bulgaria | 1527 | |
| 81 | Novo Nordisk Investigational Site | Sofia | Bulgaria | 1606 | |
| 82 | Novo Nordisk Investigational Site | Sofia | Bulgaria | 1618 | |
| 83 | Novo Nordisk Investigational Site | Stara Zagora | Bulgaria | 6000 | |
| 84 | Novo Nordisk Investigational Site | Varna | Bulgaria | 9010 | |
| 85 | Novo Nordisk Investigational Site | Calgary | Alberta | Canada | T2H 2G4 |
| 86 | Novo Nordisk Investigational Site | Calgary | Alberta | Canada | T2V 4J2 |
| 87 | Novo Nordisk Investigational Site | Moncton | New Brunswick | Canada | E1G 1A7 |
| 88 | Novo Nordisk Investigational Site | Barrie | Ontario | Canada | L4N 7L3 |
| 89 | Novo Nordisk Investigational Site | Brampton | Ontario | Canada | L6S 0C6 |
| 90 | Novo Nordisk Investigational Site | Cambridge | Ontario | Canada | N1R 6V6 |
| 91 | Novo Nordisk Investigational Site | Hamilton | Ontario | Canada | L8M 1K7 |
| 92 | Novo Nordisk Investigational Site | Peterborough | Ontario | Canada | K9J 0B2 |
| 93 | Novo Nordisk Investigational Site | Toronto | Ontario | Canada | M6G 1M2 |
| 94 | Novo Nordisk Investigational Site | Waterloo | Ontario | Canada | N2T 0C1 |
| 95 | Novo Nordisk Investigational Site | Brossard | Quebec | Canada | J4Z-2K9 |
| 96 | Novo Nordisk Investigational Site | Laval | Quebec | Canada | H7T 2P5 |
| 97 | Novo Nordisk Investigational Site | Mirabel | Quebec | Canada | J7J 2K8 |
| 98 | Novo Nordisk Investigational Site | Montreal | Quebec | Canada | H4A 3T2 |
| 99 | Novo Nordisk Investigational Site | Québec | Quebec | Canada | G1V 4W2 |
| 100 | Novo Nordisk Investigational Site | Sherbrooke | Quebec | Canada | J1H 5H3 |
| 101 | Novo Nordisk Investigational Site | Terrebonne | Quebec | Canada | J6X 4P7 |
| 102 | Novo Nordisk Investigational Site | Nova Scotia | Canada | B3H 2Y9 | |
| 103 | Novo Nordisk Investigational Site | Quebec | Canada | G1V 4G5 | |
| 104 | Novo Nordisk Investigational Site | Barranquilla | Colombia | 080020 | |
| 105 | Novo Nordisk Investigational Site | Barranquilla | Colombia | 80020 | |
| 106 | Novo Nordisk Investigational Site | Bogota | Colombia | 110221 | |
| 107 | Novo Nordisk Investigational Site | Bucaramanga-piedecuesta, Valle Del Menzuli - Santander | Colombia | 681012 | |
| 108 | Novo Nordisk Investigational Site | Rionegro | Colombia | 054040 | |
| 109 | Novo Nordisk Investigational Site | Soledad | Colombia | 83001 | |
| 110 | Novo Nordisk Investigational Site | Aarhus N | Denmark | 8200 | |
| 111 | Novo Nordisk Investigational Site | Hellerup | Denmark | 2900 | |
| 112 | Novo Nordisk Investigational Site | Holbæk | Denmark | 4300 | |
| 113 | Novo Nordisk Investigational Site | Svendborg | Denmark | 5700 | |
| 114 | Novo Nordisk Investigational Site | Viborg | Denmark | 8800 | |
| 115 | Novo Nordisk Investigational Site | Annonay | France | 07100 | |
| 116 | Novo Nordisk Investigational Site | Bobigny | France | 93009 | |
| 117 | Novo Nordisk Investigational Site | Grenoble - Cédex 09 | France | 38043 | |
| 118 | Novo Nordisk Investigational Site | Le Coudray | France | 28630 | |
| 119 | Novo Nordisk Investigational Site | Montpellier | France | 34295 | |
| 120 | Novo Nordisk Investigational Site | Paris | France | 75013 | |
| 121 | Novo Nordisk Investigational Site | Dortmund | Germany | 44137 | |
| 122 | Novo Nordisk Investigational Site | Dresden | Germany | 01307 | |
| 123 | Novo Nordisk Investigational Site | Essen | Germany | 45136 | |
| 124 | Novo Nordisk Investigational Site | Frankfurt | Germany | 60389 | |
| 125 | Novo Nordisk Investigational Site | Hamburg | Germany | 21109 | |
| 126 | Novo Nordisk Investigational Site | Hamburg | Germany | 22607 | |
| 127 | Novo Nordisk Investigational Site | Heidelberg | Germany | 69120 | |
| 128 | Novo Nordisk Investigational Site | Leipzig | Germany | 04103 | |
| 129 | Novo Nordisk Investigational Site | Münster | Germany | 48145 | |
| 130 | Novo Nordisk Investigational Site | Münster | Germany | 48149 | |
| 131 | Novo Nordisk Investigational Site | Oldenburg I. Holst | Germany | 23758 | |
| 132 | Novo Nordisk Investigational Site | Witten | Germany | 58455 | |
| 133 | Novo Nordisk Investigational Site | Hyderabad | Andhra Pradesh | India | 500072 |
| 134 | Novo Nordisk Investigational Site | Vijayawada | Andhra Pradesh | India | 520002 |
| 135 | Novo Nordisk Investigational Site | Guwahati | Assam | India | 781033 |
| 136 | Novo Nordisk Investigational Site | Ahmedabad | Gujarat | India | 380060 |
| 137 | Novo Nordisk Investigational Site | Vadodara | Gujarat | India | 390022 |
| 138 | Novo Nordisk Investigational Site | Mangalore | Karnataka | India | 575002 |
| 139 | Novo Nordisk Investigational Site | Mysore | Karnataka | India | 570001 |
| 140 | Novo Nordisk Investigational Site | Aurangabad | Maharashtra | India | 431005 |
| 141 | Novo Nordisk Investigational Site | Ansari Nagar | New Delhi | India | 110029 |
| 142 | Novo Nordisk Investigational Site | Delhi | New Delhi | India | 110076 |
| 143 | Novo Nordisk Investigational Site | Bhubaneswar | Orissa | India | 751030 |
| 144 | Novo Nordisk Investigational Site | Khurda | Orissa | India | 751019 |
| 145 | Novo Nordisk Investigational Site | Ludhiana | Punjab | India | 141008 |
| 146 | Novo Nordisk Investigational Site | Mohali | Punjab | India | 160062 |
| 147 | Novo Nordisk Investigational Site | Coimbatore | Tamil Nadu | India | 641018 |
| 148 | Novo Nordisk Investigational Site | Lucknow | Uttar Pradesh | India | 226014 |
| 149 | Novo Nordisk Investigational Site | Aligarh | India | 202002 | |
| 150 | Novo Nordisk Investigational Site | Bangalore | India | 560 099 | |
| 151 | Novo Nordisk Investigational Site | Jodhpur | India | 342005 | |
| 152 | Novo Nordisk Investigational Site | Nagpur | India | 441108 | |
| 153 | Novo Nordisk Investigational Site | Nashik | India | 422005 | |
| 154 | Novo Nordisk Investigational Site | New Delhi | India | 110002 | |
| 155 | Novo Nordisk Investigational Site | New Delhi | India | 110005 | |
| 156 | Novo Nordisk Investigational Site | New Delhi | India | 110060 | |
| 157 | Novo Nordisk Investigational Site | Pune | India | 411001 | |
| 158 | Novo Nordisk Investigational Site | Dublin | Leinster | Ireland | DUBLIN 4 |
| 159 | Novo Nordisk Investigational Site | Latina | LT | Italy | 04100 |
| 160 | Novo Nordisk Investigational Site | Mirano | Venezia | Italy | 30035 |
| 161 | Novo Nordisk Investigational Site | Bologna | Italy | 40138 | |
| 162 | Novo Nordisk Investigational Site | Firenze | Italy | 50134 | |
| 163 | Novo Nordisk Investigational Site | Milano | Italy | 20157 | |
| 164 | Novo Nordisk Investigational Site | Modena | Italy | 41126 | |
| 165 | Novo Nordisk Investigational Site | Palermo | Italy | 90127 | |
| 166 | Novo Nordisk Investigational Site | Pisa | Italy | 56126 | |
| 167 | Novo Nordisk Investigational Site | Roma | Italy | 00128 | |
| 168 | Novo Nordisk Investigational Site | Rome | Italy | 00168 | |
| 169 | Novo Nordisk Investigational Site | San Donato Milanese (MI) | Italy | 20097 | |
| 170 | Novo Nordisk Investigational Site | Siena | Italy | 53100 | |
| 171 | Novo Nordisk Investigational Site | Chiba-shi, Chiba | Japan | 260-0804 | |
| 172 | Novo Nordisk Investigational Site | Ehime | Japan | 790-0034 | |
| 173 | Novo Nordisk Investigational Site | Ibaraki | Japan | 311-0113 | |
| 174 | Novo Nordisk Investigational Site | Minato-ku, Tokyo | Japan | 108-0073 | |
| 175 | Novo Nordisk Investigational Site | Mito-shi, Ibaraki | Japan | 311-4153 | |
| 176 | Novo Nordisk Investigational Site | Okinawa | Japan | 901-0493 | |
| 177 | Novo Nordisk Investigational Site | Osaka-city, Osaka | Japan | 530-0001 | |
| 178 | Novo Nordisk Investigational Site | Osaka | Japan | 530-0001 | |
| 179 | Novo Nordisk Investigational Site | Osaka | Japan | 574-0074 | |
| 180 | Novo Nordisk Investigational Site | Saga | Japan | 849-8501 | |
| 181 | Novo Nordisk Investigational Site | Takamatsu-shi, Kagawa | Japan | 760-8557 | |
| 182 | Novo Nordisk Investigational Site | Tokyo | Japan | 103-0027 | |
| 183 | Novo Nordisk Investigational Site | Tokyo | Japan | 104-0031 | |
| 184 | Novo Nordisk Investigational Site | Yao-shi, Osaka | Japan | 581-0011 | |
| 185 | Novo Nordisk Investigational Site | Cuernavaca | Morelos | Mexico | 62250 |
| 186 | Novo Nordisk Investigational Site | San Luis Potosí | San Luis Potosi | Mexico | 78200 |
| 187 | Novo Nordisk Investigational Site | Xalapa | Veracruz | Mexico | 91193 |
| 188 | Novo Nordisk Investigational Site | Aguascalientes | Mexico | 20230 | |
| 189 | Novo Nordisk Investigational Site | Guadalajara | Mexico | 44670 | |
| 190 | Novo Nordisk Investigational Site | Apeldoorn | Netherlands | 7334 DZ | |
| 191 | Novo Nordisk Investigational Site | Gouda | Netherlands | 2803HH | |
| 192 | Novo Nordisk Investigational Site | Groningen | Netherlands | 9713 GZ | |
| 193 | Novo Nordisk Investigational Site | Leeuwarden | Netherlands | 8934 AD | |
| 194 | Novo Nordisk Investigational Site | Nijmegen | Netherlands | 6525 GA | |
| 195 | Novo Nordisk Investigational Site | Rotterdam | Netherlands | 3045 PM | |
| 196 | Novo Nordisk Investigational Site | Sneek | Netherlands | 8601 ZR | |
| 197 | Novo Nordisk Investigational Site | Tiel | Netherlands | 4002 WP | |
| 198 | Novo Nordisk Investigational Site | Poznan | Wielkopolskie | Poland | 60-589 |
| 199 | Novo Nordisk Investigational Site | Bialystok | Poland | 15-276 | |
| 200 | Novo Nordisk Investigational Site | Bygdoszcz | Poland | 85-796 | |
| 201 | Novo Nordisk Investigational Site | Dabrowka | Poland | 62-069 | |
| 202 | Novo Nordisk Investigational Site | Gorzow Wielkopolski | Poland | 66-400 | |
| 203 | Novo Nordisk Investigational Site | Katowice | Poland | 40-555 | |
| 204 | Novo Nordisk Investigational Site | Lodz | Poland | 93-513 | |
| 205 | Novo Nordisk Investigational Site | Zabrze | Poland | 41-800 | |
| 206 | Novo Nordisk Investigational Site | Belgrade | Serbia | 11000 | |
| 207 | Novo Nordisk Investigational Site | Belgrade | Serbia | 11080 | |
| 208 | Novo Nordisk Investigational Site | Kragujevac | Serbia | 34000 | |
| 209 | Novo Nordisk Investigational Site | Novi Sad | Serbia | 21000 | |
| 210 | Novo Nordisk Investigational Site | Johannesburg | Gauteng | South Africa | 1818 |
| 211 | Novo Nordisk Investigational Site | Johannesburg | Gauteng | South Africa | 1827 |
| 212 | Novo Nordisk Investigational Site | Johannesburg | Gauteng | South Africa | 2193 |
| 213 | Novo Nordisk Investigational Site | Pretoria | Gauteng | South Africa | 0002 |
| 214 | Novo Nordisk Investigational Site | Pretoria | Gauteng | South Africa | 0083 |
| 215 | Novo Nordisk Investigational Site | Pretoria | Gauteng | South Africa | 0157 |
| 216 | Novo Nordisk Investigational Site | Pretoria | Gauteng | South Africa | 0181 |
| 217 | Novo Nordisk Investigational Site | Durban | KwaZulu-Natal | South Africa | 4320 |
| 218 | Novo Nordisk Investigational Site | Cape Town | Western Cape | South Africa | 7500 |
| 219 | Novo Nordisk Investigational Site | Cape Town | Western Cape | South Africa | 7925 |
| 220 | Novo Nordisk Investigational Site | Cape Town | Western Cape | South Africa | 7935 |
| 221 | Novo Nordisk Investigational Site | Mossel Bay | Western Cape | South Africa | 6506 |
| 222 | Novo Nordisk Investigational Site | Fuenlabrada | Madrid | Spain | 28942 |
| 223 | Novo Nordisk Investigational Site | Barcelona | Spain | 08035 | |
| 224 | Novo Nordisk Investigational Site | Castilleja Dela Cuesta Sevilla | Spain | 41950 | |
| 225 | Novo Nordisk Investigational Site | Madrid | Spain | 28007 | |
| 226 | Novo Nordisk Investigational Site | Málaga | Spain | 29010 | |
| 227 | Novo Nordisk Investigational Site | Palma de Mallorca | Spain | 07120 | |
| 228 | Novo Nordisk Investigational Site | Pozuelo de Alarcón | Spain | 28223 | |
| 229 | Novo Nordisk Investigational Site | Sevilla | Spain | 41003 | |
| 230 | Novo Nordisk Investigational Site | Valencia | Spain | 46014 | |
| 231 | Novo Nordisk Investigational Site | Ankara | Bahcelievler | Turkey | 06490 |
| 232 | Novo Nordisk Investigational Site | Eskisehir | Odunpazari | Turkey | 26040 |
| 233 | Novo Nordisk Investigational Site | Adana | Turkey | 01000 | |
| 234 | Novo Nordisk Investigational Site | Adana | Turkey | 01250 | |
| 235 | Novo Nordisk Investigational Site | Afyon | Turkey | 03200 | |
| 236 | Novo Nordisk Investigational Site | Edirne | Turkey | 22030 | |
| 237 | Novo Nordisk Investigational Site | Istanbul | Turkey | 111 | |
| 238 | Novo Nordisk Investigational Site | Istanbul | Turkey | 34098 | |
| 239 | Novo Nordisk Investigational Site | Istanbul | Turkey | 34371 | |
| 240 | Novo Nordisk Investigational Site | Istanbul | Turkey | 34722 | |
| 241 | Novo Nordisk Investigational Site | Izmir | Turkey | 35340 | |
| 242 | Novo Nordisk Investigational Site | Kahramanmaras | Turkey | 46040 | |
| 243 | Novo Nordisk Investigational Site | Kayseri | Turkey | 38039 | |
| 244 | Novo Nordisk Investigational Site | Kocaeli | Turkey | 41380 | |
| 245 | Novo Nordisk Investigational Site | Mersin | Turkey | 33343 | |
| 246 | Novo Nordisk Investigational Site | Blackpool | Lancashire | United Kingdom | FY3 8NR |
| 247 | Novo Nordisk Investigational Site | Bradford | United Kingdom | BD9 6RJ | |
| 248 | Novo Nordisk Investigational Site | Coventry | United Kingdom | CV2 2DX | |
| 249 | Novo Nordisk Investigational Site | Exeter | United Kingdom | EX2 5DW | |
| 250 | Novo Nordisk Investigational Site | Hull | United Kingdom | HU3 2JZ | |
| 251 | Novo Nordisk Investigational Site | Leicester | United Kingdom | LE5 4PW | |
| 252 | Novo Nordisk Investigational Site | Newcastle upon Tyne | United Kingdom | NE4 6BE | |
| 253 | Novo Nordisk Investigational Site | Soham | United Kingdom | CB7 5JD | |
| 254 | Novo Nordisk Investigational Site |
Sponsors and Collaborators
- Novo Nordisk A/S
Investigators
- Study Director: Clinical Transparency dept. 2834, Novo Nordisk A/S
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT05669755
Other Study ID Numbers:
- NN9838-4942
- U1111-1270-0943
- 2021-005855-35
First Posted:
Jan 3, 2023
Last Update Posted:
Jan 25, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: